Stocktoria
Bio Essence Corp BIOE
OTC · stock · Pharmaceutical Preparations · website · IPO 2022-03-30
Bio Essence Corp financials (annual, from 10-K)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $323,940 | $551,506 | $621,590 | $887,984 | $958,700 |
| Gross profit | $1.4M | $217,077 | $277,446 | $328,326 | $298,324 | $227,287 |
| Operating income | $900,011 | -$459,438 | -$345,590 | -$511,138 | -$857,527 | -$832,566 |
| Interest expense | — | — | $17,344 | $14,131 | $38,558 | $41,900 |
| Income tax | $800 | $800 | $1,600 | $2,500 | $3,300 | $3,300 |
| Net income | $896,197 | -$1.3M | -$971,879 | -$809,679 | -$647,564 | -$595,838 |
| EPS (diluted) | — | $-0.03 | $-0.03 | $-0.02 | $-0.02 | — |
| Operating cash flow | $1.6M | $639,817 | -$1.0M | -$703,241 | -$1.3M | -$732,744 |
| Free cash flow | — | — | -$1.0M | -$706,983 | -$1.4M | -$740,109 |
| Cash & equivalents | — | $1,371 | $114 | $6,262 | $303 | $5,325 |
| Inventory | — | — | $143,259 | $181,163 | $212,969 | $272,232 |
| Total assets | $422,474 | $281,024 | $2.8M | $1.5M | $1.7M | $1.8M |
| Total liabilities | $2.5M | $3.3M | $4.4M | $4.8M | $4.1M | $3.6M |
| Shareholders' equity | -$2.1M | -$3.0M | -$1.7M | -$3.2M | -$2.4M | -$1.8M |
Growth · year-over-year · Revenue CAGR 14.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +485.8% | -41.3% | -11.3% | -30.0% | -7.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001723059 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.